Lakefront Biotherapeutics NV Stock
Stocks
LKFT
BE0003818359
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Amsterdam
19:55:00 21/09/2026 +04
|
After hours 23:48:53 | |||
| 25.64 EUR | +2.64% |
|
25.79 | +0.59% |
| Market Cap | 1.62B 1.86B 1.53B 1.39B 2.61B 178B 2.61B 18.31B 7.06B 90.86B 6.99B 6.84B 293B | P/E 2026 * |
-13.2x | P/E 2027 * | -5.36x |
|---|---|---|---|---|---|
| Enterprise Value | -807M -926M -760M -692M -1.3B -88.7B -1.3B -9.11B -3.51B -45.18B -3.48B -3.4B -146B | EV / Sales 2026 * |
-8.51x | EV / Sales 2027 * | 1.38x |
| Free-Float |
74.64% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Amsterdam
| LKFT | Real-time | |
CBOE
| LKFT | Real-time | |
|
Xetra
| GXE | End-of-day quote | |
|
Tradegate
| GXE | Real-time | |
|
CBOE
| 0JXZ | Real-time | |
|
OTC Markets
| GLPGF | Delayed | |
|
Xetra
| GXE | Delayed | |
|
Deutsche Boerse AG
| GXE | Delayed | |
|
London S.E.
| 0JXZ | Delayed | |
|
Wiener Boerse
| LKFT | End-of-day quote | |
|
Börse Stuttgart
| GXE | Delayed | |
|
Boerse Muenchen
| GXE | Real-time | |
|
Borsa Italiana
| 4LKFT | End-of-day quote |
Last Transcript: Lakefront Biotherapeutics NV
| 09-16 | Acquisition of Own Shares | GL |
| 09-09 | Acquisition of Own Shares | GL |
| 09-09 | Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference | GL |
| 09-02 | Acquisition of Own Shares | GL |
| 08-26 | Acquisition of Own Shares | GL |
| 1 day | +2.64% | ||
| 1 week | +9.76% | ||
| Current month | +4.40% | ||
| 1 month | +2.89% | ||
| 3 months | +2.72% | ||
| 6 months | -6.76% | ||
| Current year | -8.43% |
| 1 week | 23.12 |  | 25.86 |
| 1 month | 23.12 | | 25.86 |
| Current year | 22.32 | | 30.72 |
| 1 year | 22.32 | | 32.74 |
| 3 years | 20 | | 39 |
| 5 years | 20 | | 66.28 |
| 10 years | 20 | | 252.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Henry Gosebruch
CEO | Chief Executive Officer | 53 | 12/05/2025 |
Aaron Cox
DFI | Director of Finance/CFO | 41 | 07/07/2025 |
| Chief Operating Officer | - | 01/06/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Linda Higgins
BRD | Director/Board Member | 63 | 22/10/2019 |
Oleg Nodelman
BRD | Director/Board Member | 49 | 07/10/2024 |
Henry Gosebruch
BRD | Director/Board Member | 53 | 12/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 28/01/26 | Buy | Director | 137 | 0.0002% | ||
| 28/01/26 | Buy | Director | 375 | 0.0006% | ||
| 28/01/26 | Free | General Counsel | 235,000 | 0.3566% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.64% | +9.76% | -10.85% | -21.85% | 1.86B | |
| +0.59% | +2.73% | +1.48% | +28.74% | 46.28B | |
| +1.32% | +1.36% | +43.37% | +35.20% | 43.85B | |
| +1.10% | -5.64% | +335.80% | +534.97% | 40.93B | |
| +4.30% | +3.36% | +8.26% | +94.75% | 39.89B | |
| +1.11% | +1.80% | +11.52% | +43.15% | 29.5B | |
| +1.99% | +4.48% | +24.90% | +158.34% | 17.09B | |
| +0.46% | -10.41% | - | - | 15.55B | |
| +2.12% | +10.41% | +24.78% | +39.05% | 15.22B | |
| -0.36% | +24.93% | -9.49% | - | 14.05B | |
| Average | +1.51% | +4.28% | +47.75% | +114.04% | 26.42B | |
| Weighted average by Cap. | +1.53% | +2.12% | +68.49% | +141.00% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 94.87M 109M 89.35M 81.37M 153M 10.42B 153M 1.07B 412M 5.31B 409M 400M 17.13B | 80.29M 92.09M 75.62M 68.87M 129M 8.82B 129M 906M 349M 4.49B 346M 338M 14.5B |
| Net income | -40.7M -46.67M -38.33M -34.91M -65.45M -4.47B -65.53M -459M -177M -2.28B -175M -171M -7.35B | -213M -244M -200M -182M -342M -23.37B -342M -2.4B -925M -11.9B -916M -896M -38.42B |
| Net Debt | -2.43B -2.79B -2.29B -2.08B -3.91B -267B -3.91B -27.41B -10.57B -136B -10.47B -10.24B -439B | -1.51B -1.73B -1.42B -1.3B -2.43B -166B -2.43B -17.06B -6.57B -84.64B -6.52B -6.37B -273B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/09/26 | €25.64 | +2.64% | 94,401 |
| 18/09/26 | €24.98 | +0.16% | 397,179 |
| 17/09/26 | €24.94 | +4.09% | 110,678 |
| 16/09/26 | €23.96 | +0.34% | 73,645 |
| 15/09/26 | €23.88 | +2.23% | 83,514 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- LKFT Stock
Select your edition
All financial news and data tailored to specific country editions
